Page 19 - Interim Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Data to highlight the safety, tolerability and efficacy of LUPKYNIS in patients with lupus nephritis Aurinia Pharmaceuticals Inc. a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ for the treatment of people with lupus nephritis a serious complication of systemic lupus erythematosus resulting in ...

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today...

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today...

>> sandra: merck put out a statement. at the interim analysis, it reduced the risk of hospitalization or death by approximately 50%. 7.3% of patients who received this were hospitalized or die day 29 following randomization compared to 14% of placebo treated patients. this is former scott gottlieb how he sees the over all impact of the pill. >> i think they will provide psychological and this drug was probably the best data i have ever seen for orally available drug with respiratory pathogen. this pill could provide a real difference in how we address this virus given the magnitude, the effect...

/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...